Evidence map›Paper›PMID 39792134›Full record

Trial reportEuropean journal of heart failure2025

Sacubitril/valsartan versus valsartan initiation in patients naïve to renin-angiotensin system inhibitors: Insights from PARAGLIDE-HF.

Nina Nouhravesh, Alexander H Gunn, Derek Cyr, Adrian F Hernandez, David A Morrow, Eric J Velazquez, Jonathan H Ward, Samiha Sarwat, Kavita Sharma, Kristin M Williamson and 5 more

Abstract readRandomized Controlled TrialMulticenter StudyComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nina NouhraveshDuke Clinical Research Institute, Durham, NC, USA.
Alexander H GunnDuke Clinical Research Institute, Durham, NC, USA.
Derek CyrDuke Clinical Research Institute, Durham, NC, USA.
Adrian F HernandezDuke Clinical Research Institute, Durham, NC, USA.
David A MorrowBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Eric J VelazquezYale School of Medicine, New Haven, CT, USA.
Jonathan H WardNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Samiha SarwatNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Kavita SharmaJohns Hopkins University School of Medicine, Baltimore, MD, USA.
Kristin M WilliamsonNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Randall C StarlingDepartment of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA.
Serge LepageUniversite de Sherbrooke, Quebec, QC, Canada.
Shelley ZierothUniversity of Manitoba, Winnipeg, MB, Canada.
Scott D SolomonBrigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Robert J MentzDuke Clinical Research Institute, Durham, NC, USA.

Funding

Novartis Pharmaceuticals Corporation
6 · The paper itself

Abstract

aimsWhether prior treatment with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) modifies efficacy and safety of sacubitril/valsartan (Sac/Val) in patients with heart failure (HF) and ejection fraction (EF) >40% is unclear, thus Sac/Val according to ACEi/ARB status at baseline was assessed. METHODS AND

resultsThis was a pre-specified analysis of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE-HF), a double-blind, randomized controlled trial of Sac/Val versus valsartan, categorizing patients according to baseline ACEi/ARB status. The primary endpoint was time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) from baseline through weeks 4 and 8. Secondary analyses included a win-ratio analysis of the hierarchical outcome of (i) cardiovascular death; (ii) HF hospitalizations; (iii) urgent HF visits; and (iv) time-averaged proportional change in NT-proBNP from baseline to weeks 4 and 8, in addition to safety outcomes. Among 466 patients, 107 (23%) were ACEi/ARB naïve at the time of randomization. NT-proBNP favoured Sac/Val irrespective of ACEi/ARB status (naïve: 0.76, 95% confidence interval [CI] 0.51-1.13; users: 0.88, 95% CI 0.74-1.05; p

conclusionIn HF with EF >40% stabilized after worsening HF, safety and efficacy were similar irrespective of ACEi/ARB status at baseline, supporting early initiation irrespective of prior ACEi/ARB use.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsHeart FailureRenin-Angiotensin SystemTetrazolesAgedAngiotensin-Converting Enzyme InhibitorsBiphenyl CompoundsDouble-Blind MethodDrug CombinationsFemaleHumansMaleMiddle AgedNatriuretic Peptide, BrainPeptide FragmentsAminobutyratesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)sacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanAcute decompensated HFpEFClinical outcomesHFmrEFNatriuretic peptidesSacubitril/valsartan

Identifiers

PMID39792134
PMCPMC12482847

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.